[Pharmaco -- genetic approach to the improvement of beta-adrenoblocker therapy in the treatment of hypertension].
A relationship between individual variations of the oxidative and acetylating metabolism rates of penbutolol, propranolol, acebutolol which produce a hypotensive effect was studied in patients with arterial hypertension. A study was performed in groups of patients, which comprised 22, 22, and 20 males, respectively. They all suffered from Stage II hypertensive disease. There was a predominant number of patients with partial and complete antihypertensive benefits in those with low oxidation rates than in those with high oxidative metabolism rates when penbutolol (89 and 54%, respectively; p < 0.05) and propranolol (78 and 31%, respectively; p < 0.01) were given. A graphic analysis of changes in blood pressure, which had been observed during a course monotherapy with penbutolol and propranolol identified two groups of patients differing in having benefits. Within each group, the relationship between the decrease in diastolic blood pressure to the elimination half-life of parmidine is described by a linear regression equation and it has a high positive correlation coefficient.
N G
NG
Filippenko
S V
SV
Povetkin
I I
II
Smirnova
N G
NG
Dementéva
V T
VT
Bredikhin
D000070:Acebutolol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010394:Penbutolol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011433:Propranolol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012044:Regression Analysis
D000070:Acebutolol; D010394:Penbutolol; D011433:Propranolol
Farmakogeneticheskiĭ podkhod k optimizatsii terapii gipertonicheskoĭ bolezni beta-adrenoblokatorami.